PB0512 - Associations of Platelete P2y12 Receptor Polymorphism with Macroangiopathies in Patients with High Cardiovascular Risk

Background: According to Aga Q.A.A. et al., the contribution of genetic factors to the variability of platelet reactivity is about 30%. Functional evaluation of the effect of polymorphic variants of the GRIbα gene on the rate of thrombosis was performed only in some small studies. Unndifferentiated the role of P2Y12 receptor polymorphism with macroangiopathies.

Aims: to establish the role of allelic polymorphisms P2RY12--744C, (GPIbα)-C482T in the development of vascular lesions in patients with arterial hypertension and diabetes mellitus type 2.

Methods: The study included 100 patients with hypertension and diabetes mellitus type 2 (main group) and 50 healthy people (control group). Patients underwent echocardiography, color duplex scanning of extracranial, brachiocephalic and femoral vessels. The distribution of allelic polymorphisms was investigated by isolation DNA from leukocytes and polymerase chain reaction (PCR).

Results: A monolocus analysis showed the presence of changes between the main and control groups (p < 0,05). The frequency distribution of alleles of the platelet glycoprotein receptor gene (C482T, GP1bα) was more uniform than the alleles of the P2RY12 receptor. Thus, the 482C allele was found in 90% of patients (its frequency in the group – 47,0 ± 1,8%), and the 482T allele - in 96% of patients (total frequency in the group – 5,0 ± 1,8%). However, the analysis of associations of the C482T polymorphic locus of the GPIbα gene revealed a probable excess of the T allele frequency in patients with macroangiopathies (OR = 3,29 in the trend test, increasing the degree of heterozygosity for the allele " risk ", increase in the degree of allelic positivity (p < 0,001)).

Conclusion(s): Thus, based on data analysis, it can be assumed that allelic polymorphisms of GPIbα gene can be considered as genetic markers of markers associated with vascular damage in the general cohort of patients with combined hypertension and type 2 diabetes.